Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Bruxelles  >  Acacia Pharma Group    ACPH   GB00BYWF9Y76

ACACIA PHARMA GROUP

(ACPH)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Bruxelles
02/12/2019 02/13/2019 02/14/2019 02/15/2019 02/18/2019 Date
1.4796(c) 1.48(c) 1.47(c) 1.47(c) 1.5188 Last
24 132 20 759 27 622 34 153 61 747 Volume
-2.13% +0.03% -0.68% 0.00% +3.32% Change
More quotes
Financials (GBP)
Sales 2018 -
EBIT 2018 -18,4 M
Net income 2018 -17,5 M
Debt 2018 -
Yield 2018 -
Sales 2019 2,50 M
EBIT 2019 -45,1 M
Net income 2019 -43,2 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 0
Capi. / Sales2019 27,7x
Capitalization 69,1 M
More Financials
Company
Acacia Pharma specializes in the research and development of supportive care medicines. The products are intended to support the side effects of anti-cancer treatments (including nausea and vomiting drugs). At the end of January 2018, the group had a portfolio of 2 products, including APD403 in... 
Sector
Pharmaceuticals
Calendar
-
More about the company
Latest news on ACACIA PHARMA GROUP
01/29ACACIA PHARMA : Editorial in Anesthesiology on Positive Data for BARHEMSYS PONV ..
AQ
01/28ACACIA PHARMA : EDITORIAL ON POSITIVE DATA FOR BARHEMSYS™ RESCUE TREATMENT..
AQ
01/23ACACIA PHARMA : Supportive Cardiac Safety Data for BARHEMSYS
AQ
01/23ACACIA PHARMA : Announces Supportive Cardiac Safety Data for Barhemsys
AQ
01/22ACACIA PHARMA : ANNOUNCES SUPPORTIVE CARDIAC SAFETY DATA FOR BARHEMSYS™
AQ
2018TR-1 : Standard form for notification of major holdings
GL
2018ACACIA PHARMA : Positive Clinical Results for APD403 in CINV Published in Suppor..
AQ
2018ACACIA PHARMA GROUP PLC : Acacia Pharma announces positive clinical results for ..
GL
2018ACACIA PHARMA : New BARHEMSYS PDUFA date confirmed for 5 May 2019
AQ
2018ACACIA PHARMA GROUP PLC : Acacia pharma announces barhemsys(tm) pdufa date of 5 ..
GL
More news
Sector news : Pharmaceuticals - NEC
02/17Cash-hoarding Japanese firms please investors as share buybacks hit record
RE
02/15BRISTOL MYERS SQUIBB : Starboard gauges Bristol-Myers shareholder support for Ce..
RE
02/15Bayer gains full Vitrakvi rights from Eli Lilly's Loxo
RE
02/15WSJ TAX GUIDE 2019 : What Investors Need to Know -2-
DJ
02/15WSJ TAX GUIDE 2019 : What Investors Need to Know -- Journal Report
DJ
More sector news : Pharmaceuticals - NEC
Chart ACACIA PHARMA GROUP
Duration : Period :
Acacia Pharma Group Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ACACIA PHARMA GROUP
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 3,81  GBP
Spread / Average Target 196%
EPS Revisions
Managers
NameTitle
Gilbert Julian Clive Chief Executive Officer & Director
Scott A. Byrd Non-Executive Director
Patrick Volkert Vink Non-Executive Chairman
Christine Helen Soden Chief Financial Officer, Secretary & Director
Gabriel Fox Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ACACIA PHARMA GROUP14.86%89
JOHNSON & JOHNSON5.68%365 768
PFIZER-2.86%245 920
ROCHE HOLDING LTD.11.98%233 242
NOVARTIS7.19%228 685
MERCK AND COMPANY4.45%207 536